CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 27, 2020
Result type: Reports
Project Number: SR0657-0000
Product Line: Common Drug Review

Generic Name: ofatumumab

Brand Name: TBC

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Multiple Sclerosis, relapsing

Manufacturer Requested Reimbursement Criteria1: For the treatment of Relapsing Multiple Sclerosis (RMS)

Submission Type: New

Project Status: Pending

Call For Patient Input: July 27, 2020

Patient Input Closed: September 16, 2020

Anticipated Date: August 25, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback